ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough esophageal cancer: QLC5508 faces chemotherapy in phase 3 showdown
Disease control Recruiting nowThis study tests a new drug called QLC5508 against standard chemotherapy for people with advanced esophageal cancer that has worsened after prior treatments. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The main go…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New combo therapy aims to make inoperable esophageal cancer removable
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug tislelizumab to standard chemoradiation can shrink advanced esophageal cancer enough to allow surgery. About 45 adults with unresectable esophageal squamous cell carcinoma will receive the combination, then possibly undergo s…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Ming-Yu Lien • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New targeted drug ALX2004 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called ALX2004 in people with advanced or metastatic solid tumors (lung, head and neck, colorectal, esophageal) that have not responded to standard treatments. ALX2004 is an antibody drug conjugate designed to deliver chemotherapy directly …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New triple therapy targets tough esophageal cancer
Disease control Recruiting nowThis study tests a new drug called KC1036 combined with immunotherapy and chemotherapy as a first treatment for people with advanced or recurrent esophageal cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors and delays cancer growth. Ab…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo therapy may let some esophageal cancer patients keep their esophagus
Disease control Recruiting nowThis study is for adults with a type of esophageal cancer (squamous cell carcinoma) that can potentially be removed with surgery. The goal is to see if giving a combination of immunotherapy (tislelizumab) and chemotherapy (carboplatin and nab-paclitaxel) before any procedure can …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Double immunotherapy attack shows promise against tough esophageal cancer
Disease control Recruiting nowThis study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy can shrink tumors and slow disease in people with advanced esophageal cancer that has come back or spread. About 25 adults whose cancer cannot be removed by surger…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Can a radiation boost beat esophageal cancer? new trial aims to find out
Disease control Recruiting nowThis early-phase trial tests whether adding a higher dose of MRI-guided radiation to standard chemoradiation can improve outcomes for people with a type of esophageal cancer. About 30 participants will receive two extra radiation boosts in the final week of standard treatment. Th…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Shorter radiation may improve esophageal cancer treatment
Disease control Recruiting nowThis study compares two types of radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. After initial chemo-immunotherapy, participants receive either a shorter course of higher-dose radiation or a standard longer course. The goal is to se…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New hope for elderly esophageal cancer patients unfit for chemo
Disease control Recruiting nowThis study tests a drug called tislelizumab in people aged 70 and older with advanced esophageal cancer who cannot receive standard chemotherapy. The main goal is to see how many patients are alive after 6 months of treatment. The drug works by helping the immune system fight can…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New combo therapy shows promise for tough esophageal cancer
Disease control Recruiting nowThis study tests a new approach for people with advanced esophageal cancer that cannot be removed by surgery. Participants will receive either a new combination of chemotherapy and immunotherapy before radiation, or the standard chemoradiation. The goal is to see which treatment …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Zunyi Medical University • Aim: Disease control
Last updated May 04, 2026 16:17 UTC
-
New blood test could spot several gut cancers before symptoms start
Diagnosis Recruiting nowThis study aims to create a blood test that can detect several types of gastrointestinal cancers—like liver, pancreatic, and colon cancer—at an early stage. Current screening methods are often invasive or not sensitive enough. The test looks for tiny molecules called miRNAs in th…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated May 12, 2026 13:40 UTC